Clinical Trials | March 09, 2026
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
DiaMedica said it plans to launch the trial later in 2026
DiaMedica said it plans to launch the trial later in 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The company announced positive topline data from the Phase II ZUPREME-1 trial
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Subscribe To Our Newsletter & Stay Updated
